Please Wait
Applying Filters...
menu
    • menu
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Ciclesonide

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 25,764Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    COVIS PHARMA GROUP Announces Top-line Safety and Efficacy Data from a Phase 3
    COVIS PHARMA GROUP Announces Top-line Safety and Efficacy Data from a Phase 3

    16 Apr 2021

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2021/04/15/2210630/11011/en/COVIS-PHARMA-GROUP-Announces-Top-line-Safety-and-Efficacy-Data-from-a-Phase-3-Placebo-Controlled-COVID-19-Study-Using-Inhaled-Corticosteroid-ciclesonide.html

    GLOBENEWSWIRE
    16 Apr 2021
    Share Share
    Covis Pharma B.V. Initiates Ph3 Clinical Trial of Alvesco Inhaler for COVID-19
    Covis Pharma B.V. Initiates Ph3 Clinical Trial of Alvesco Inhaler for COVID-19

    20 May 2020

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/covis-pharma-bv-initiates-phase-3-clinical-trial-of-alvesco-ciclesonide-inhaler-for-the-treatment-of-covid-19-301061105.html

    PR NEWSWIRE
    20 May 2020
    Share Share
    MHLW to Accept Applications for COVID-19 Treatments Without Clinical Trial
    MHLW to Accept Applications for COVID-19 Treatments Without Clinical Trial

    14 May 2020

    // JIHO

    https://pj.jiho.jp/article/242087

    JIHO
    14 May 2020
    Share Share
    AstraZeneca offloads more Seroquel rights, this time to Cheplapharm for $42M
    AstraZeneca offloads more Seroquel rights, this time to Cheplapharm for $42M

    04 Dec 2019

    // E. Sagonowsky FIERCE PHARMA

    https://www.fiercepharma.com/pharma/astrazeneca-sells-u-s-canada-seroquel-rights-to-cheplapharm-for-up-to-42m

    E. Sagonowsky FIERCE PHARMA
    04 Dec 2019
    Share Share
    Committee for Medicinal Products for Veterinary Use (CVMP) meeting
    Committee for Medicinal Products for Veterinary Use (CVMP) meeting

    08 Nov 2019

    // EMA

    https://www.ema.europa.eu/en/news/committee-medicinal-products-veterinary-use-cvmp-meeting-5-7-november-2019

    EMA
    08 Nov 2019
    Share Share
    Takeda to Acquire Select Portfolio from Neutec, Significantly Enhancing its Business in Turkey
    Takeda to Acquire Select Portfolio from Neutec, Significantly Enhancing its Business in Turkey

    25 Feb 2015

    // Press Release TAKEDA

    http://www.takeda.com/news/2015/20150224_6916.html

    Press Release TAKEDA
    25 Feb 2015
    Share Share